A071702: A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent Glioblastoma

The following study has recently been activated for patient enrollment by The University of Illinois Cancer Center Clinical Trials Office (CTO). Click on the link to learn about the details regarding the study on clinicaltrials.gov. For more information or questions about a study, email cancertrials@uic.edu or call 312-355-5112.

A071702: A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent Glioblastoma

Sponsor: National Cancer Institute (NCI)
Principal Investigator: Stefania Maraka, MD